Sep 22, 2021 / 08:30PM GMT
Operator
Good afternoon, and welcome to the Onconova Therapeutics webinar. (Operator Instructions) As a reminder, this webcast is being recorded today, September 22, 2021.
At this time, I would like to turn the call over to Avi Oler, Senior Vice President of Corporate Development and General Counsel.
Abraham N. Oler - Onconova Therapeutics, Inc. - Senior VP of Corporate Development & General Counsel
Thank you, Tara. Good afternoon, everyone, and welcome to today's webinar. Earlier today, Onconova issued a press release announcing preliminary data from the Phase I/IIa investigator-initiated trial of oral rigosertib plus nivolumab in advanced KRAS-mutated non-small cell lung cancer, which is the topic of today's discussion. The data to be reviewed was presented at the RAS-Targeted Drug Development Summit earlier today. A copy of this press release as well as a replay of today's webinar can be found on the Investors and Media page of the Onconova website.
Before we begin, I'd like to remind everyone that statements made in the press release and during
Onconova Therapeutics Inc Expert Overview from Key Opinion Leaders Webinar Transcript
Feb 29, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers